Aficamten - CAS# 2364554-48-1 Catalog No.:M33502-2 Smiles: CN([C@H]1CN(CC[C@H]1C)C(=O)CC#N)C1N=CN=C2NC=CC2=1

Smiles: CN([C@H]1CN(CC[C@H]1C)C(=O)CC#N)C1N=CN=C2NC=CC2=1

13)4-2-15(9(19)14-8(4)18)7-1-5(17)6(3-16)20-7/h2

Isocryptotanshinone inhibits the constitutive STAT3 and p-STAT3 (Y705) expression in concentration and time-dependent manners

3)36-24(35)30-19(15-17-9-5-4-6-10-17)22(34)31-14-8-12-20(31)21(33)29-18(16-32)11-7-13-28-23(26)27

To test whether GSTO1-IN-1 had in vivo efficacy

Aficamten - CAS# 2364554-48-1 Catalog No.:M33502-2 Smiles: CN([C@H]1CN(CC[C@H]1C)C(=O)CC#N)C1N=CN=C2NC=CC2=1Aficamten, CAS No. 2364554 48 1, also known as CK 3773274 and CK 274, is a Next Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy. Aficamten was designed to provide a predicted human half life (t1 2) appropriate for once a day (qd) dosing, to reach steady state within two weeks, to have no substantial cytochrome P450 induction or inhibition, and to have a wide therapeutic window in vivo with a clear pharmacokinetic